Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > How is it possible
View:
Post by 99942Apophis on Jun 15, 2023 9:53am

How is it possible

I just saw Keytruda's add on TV for their NSCLC,  are you kidding me. Their list of possible adverse effects seem to take longer than the benefits of the treatment. Really looks like Theralase's future treatment will be a welcome relief for patients,  that is if they can demonstrate a moderate to high response rate. Glad to be a shareholder in this stock, yeah baby.
Comment by Gooseybear on Jun 15, 2023 9:04pm
When I mentioned Keytruda as a possible alternative to BCG he was very much against it due to significant side effects of Keytruda.
Comment by Gooseybear on Jun 15, 2023 9:04pm
The conversation was with my Urologist.
Comment by 99942Apophis on Jun 16, 2023 11:26am
Thank you for sharing your personal experience with us Gooseybear.  Someone posted here awhile ago that its doctors and insurance companies that are the largest contributors to a new treatments revenue stream. Theralase has recently shared its high and impressive data at the AUA meeting along with Roger's interview appears to be the start of getting the word out that there is very soon to ...more  
Comment by Galaxym31 on Jun 16, 2023 12:52pm
I thought the word was out in 2015 .
Comment by gebremeskel on Jun 16, 2023 1:28pm
It was out, but it had to be taken back in because it was not suitably accoutred. This time the word will be fully decked out with a staggering list of benefits along with information on where to get your very own TLD1433 PDT for high-grade BCG-unresponsive NMIBC. 
Comment by Gooseybear on Jun 16, 2023 8:22pm
I push Theralase every chance I get with my Urologist. He is aware of the company, but has mentioned that some companies appear to be too self serving in presenting alternative treatments to BCG. I think that investing in capital for new treatments is a drawback in my Urologist situation as he recently moved to his new practice.
Comment by Alamir1111 on Jun 16, 2023 11:32pm
Hi Gossy  hang on man old expression can't teach old dogs new tricks  Don't bite hand that feed you  That should change soon
Comment by Alamir1111 on Jun 16, 2023 11:56pm
Cmon big pharma save yourselfs from embarresmant Do a 20x offer
Comment by Alamir1111 on Jun 17, 2023 12:12am
This procedure is as simple like circumsision Don't need no gene editing cart t bs .
Comment by Alamir1111 on Jun 17, 2023 12:18am
Just messing with the new al
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250